Literature DB >> 17266502

Biochemical mechanisms of cisplatin cytotoxicity.

Victoria Cepeda1, Miguel A Fuertes, Josefina Castilla, Carlos Alonso, Celia Quevedo, Jose M Pérez.   

Abstract

Since the discovery by Rosenberg and collaborators of the antitumor activity of cisplatin 35 years ago, three platinum antitumor drugs (cisplatin, carboplatin and oxaliplatin) have enjoyed a huge clinical and commercial hit. Ever since the initial discovery of the anticancer activity of cisplatin, major efforts have been devoted to elucidate the biochemical mechanisms of antitumor activity of cisplatin in order to be able to rationally design novel platinum based drugs with superior pharmacological profiles. In this report we attempt to provide a current picture of the known facts pertaining to the mechanism of action of the drug, including those involved in drug uptake, DNA damage signals transduction, and cell death through apoptosis or necrosis. A deep knowledge of the biochemical mechanisms, which are triggered in the tumor cell in response to cisplatin injury not only may lead to the design of more efficient platinum antitumor drugs but also may provide new therapeutic strategies based on the biochemical modulation of cisplatin activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266502     DOI: 10.2174/187152007779314044

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  157 in total

1.  Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer.

Authors:  Navjotsingh Pabla; Guie Dong; Man Jiang; Shuang Huang; M Vijay Kumar; Robert O Messing; Zheng Dong
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery.

Authors:  Adem Guven; Irene A Rusakova; Michael T Lewis; Lon J Wilson
Journal:  Biomaterials       Date:  2011-11-12       Impact factor: 12.479

3.  Activation and involvement of p53 in cisplatin-induced nephrotoxicity.

Authors:  Qingqing Wei; Guie Dong; Tianxin Yang; Judit Megyesi; Peter M Price; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2007-08-01

4.  hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis.

Authors:  Navjotsingh Pabla; Zhengwei Ma; Michael A McIlhatton; Richard Fishel; Zheng Dong
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

Review 5.  Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Authors:  Xue Xue; Matthew D Hall; Qiang Zhang; Paul C Wang; Michael M Gottesman; Xing-Jie Liang
Journal:  ACS Nano       Date:  2013-12-10       Impact factor: 15.881

Review 6.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.

Authors:  Darren Lars Stirland; Joseph W Nichols; Seiji Miura; You Han Bae
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

7.  Dibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes.

Authors:  Tushar S Basu Baul; Anup Paul; Lorenzo Pellerito; Michelangelo Scopelliti; Palwinder Singh; Pooja Verma; Andrew Duthie; Dick de Vos; Edward R T Tiekink
Journal:  Invest New Drugs       Date:  2009-12-11       Impact factor: 3.850

8.  Peptide targeting of platinum anti-cancer drugs.

Authors:  Margaret W Ndinguri; Rajasree Solipuram; Robert P Gambrell; Sita Aggarwal; Robert P Hammer
Journal:  Bioconjug Chem       Date:  2009-09-23       Impact factor: 4.774

9.  Nuclear EGFR is required for cisplatin resistance and DNA repair.

Authors:  Sheng-Chieh Hsu; Stephanie A Miller; Yan Wang; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2009-03-08       Impact factor: 4.060

10.  Heat shock factor 1 induces crystallin-αB to protect against cisplatin nephrotoxicity.

Authors:  Qiang Lou; Yanzhong Hu; Yuanfang Ma; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.